Drug manufacturer Boehringer Ingelheim announced this morning that, starting Aug. 1, all covered entity types will be subject to its conditions on 340B pricing when entities use contract pharmacies to dispense BI products. Until now, its conditions have applied to
…
Six Democratic and Republican U.S. senators this morning asked 340B drug pricing program stakeholders for input on “bipartisan policy solutions that would ensure the program has stability and oversight to continue to achieve its original intention of serving eligible patients.”
…
Biopharmaceutical manufacturer Exelixis said today it is extending its conditions on 340B pricing to contract pharmacies that are wholly owned or under common ownership with a hospital covered entity. The change is effective June 26.
Exelixis announced the change in
…
Drug manufacturer Teva today became the 23rd drug manufacturer to impose conditions on 340B pricing involving delivery to contract pharmacies.
Covered entities reported getting Teva’s notice by email around 1:00 p.m. Eastern. It said effective July 5:
Connecticut lawmakers are expected soon to pass a significantly revised version of Gov. Ned Lamont’s (D) health care cost reduction bill stripped of language that would have barred drug manufacturers from limiting use of contract pharmacies and imposing other conditions
…
Drug manufacturer Organon, the Merck spinoff with a focus on women’s health, today became the 22nd drug maker to impose conditions on 340B pricing involving delivery to contract pharmacies.
Covered entities began receiving an email from Organon around 3:00 p.m.
…
Drug manufacturer Novo Nordisk today announced that effective July 1 it will stop letting hospitals place bill to / ship to orders of 340B-purchased drugs to an unlimited number of contract pharmacies in exchange for related claims data.
It will,
…
Drug manufacturer Merck today stiffened its conditions on 340B pricing when hospitals and community health centers use contract pharmacies to dispense most Merck drugs to patients.
Merck told covered entities about the changes in a letter delivered by email
…
Drug manufacturer Bayer this morning significantly tightened its limits on 340B pricing when hospital covered entities contract with pharmacies to dispense drugs to patients. Grantee entities remain exempt from Bayer’s restrictions.
Covered entities reported receiving letters from Bayer about
…*Sign up for news summaries and alerts from 340B Report